Prime Minister Narendra Modi and European Commission President Ursula von der Leyen, have jointly announced the conclusion of the India–European Union Free Trade Agreement (India–EU FTA) at the 16th India–EU Summit, held during the visit of the European leaders to India. This announcement marks a historic milestone in India–EU economic relations and trade engagement with key global partners.

The European Union is India’s one of the largest trading partner, with bilateral trade in goods and services growing steadily over the years. In 2024–25, India’s bilateral trade in goods with the EU stood at Rs 11.5 Lakh Crore ($136.54 billion) with exports worth Rs 6.4 Lakh Crore ($75.85 billion) and imports amounting to $5.1 Lakh Crore ($60.68 billion). India-EU trade in services reached Rs 7.2 Lakh Crore ($83.10 billion) in 2024. Read More

In an effort to enable faster commencement of Bioavailability/Bioequivalence (BA/BE) studies, particularly for the generic pharmaceutical industry in certain low-risk categories, the Union health ministry has amended the New Drugs and Clinical Trials (NDCT) Rules, 2019.

The amendment would allow the industry to conduct studies after submission of an online application as prior intimation and obtaining an acknowledgement from the Central Licensing Authority (CLA), subject to certain conditions. Read More

The Committee for Control and Supervision of Experiments on Animals (CCSEA) has announced the schedule for inspection of animal facilities of Clinical Research Organisations (CROs), Research and Development (R&D) laboratories and other research establishments, along with guidelines and Standard Operating Procedures (SoPs) for inspection.

The move is to streamline the processes of inspection, protocol review, institutional feedback and ethical compliance, said the Committee while announcing the structured processes. The guidelines and directions are for immediate implementation by all the establishments registered with the CCSEA and nominees of the Committee. "All establishments shall ensure full cooperation, availability of responsible personnel, access to facilities and records, and adherence to all regulatory requirements, during inspections," said the Committee. Read More

The Department of Pharmaceuticals (DoP) has invited applications from eligible stakeholders to set up common facilities for medical device clusters in the country, under the scheme for Strengthening of Medical Device Industry (SMDI).

It has also extended the timeline for submission of applications for two sub-schemes under the scheme, for which the DoP has called for applications recently, till the end of this month. The move is part of its efforts to support the domestic medical devices industry in the country and strengthen its operations to reduce import dependence and clinical studies. Read More

As part of its efforts to regulate the medical devices in the country, the Drugs Controller General (India) has issued a notice classifying 77 medical devices pertaining to oncology under the provisions of Medical Devices Rules (MDR), 2017. The drug regulator has been classifying the medical devices sold in the country based on the perceived risk of the product type and its use in patients.

The measure is to help the authority to bring in all the medical devices under the regulatory control. In the latest notice, four devices are classified under the risk Class A - single use cervical cone knife and cervical cytology scraper, extracorporeal extravascular-circulation hyperthermia system applicator, and tele thermographic system. Read More

The U.S. Food and Drug Administration today published draft guidance designed to facilitate the use of Bayesian methodologies in clinical trials of drugs and biologics, helping drug developers make better use of available data, conduct more efficient clinical trials, and deliver safe and effective treatments to patients sooner. 

"Bayesian methodologies help address two of the biggest problems of drug development: high costs and long timelines,” said FDA Commissioner Marty Makary, M.D., M.P.H. “Providing clarity around modern statistical methods will help sponsors bring more cures and meaningful treatments to patients faster and more affordably.” Read More

On January 18, 2026, Dr. Manish A. Rachchh – Director & CEO, Accuprec Research Labs Pvt. Ltd. & Registered Patent Agent (IN/PA-1573) – was invited as a distinguished panelist at the inaugural UP Health Tech Conclave 1.0, organized by the UP Promote Pharma Council at Clarks Avadh, Lucknow.

In the highly engaging panel discussion titled "Leveraging and Elevating India's Manufacturing and Testing Ecosystem for Medical Device" - Dr. Manish Rachchh shared expert insights on advancing India's MedTech sector, drawing from his extensive experience in R&D, innovation in pharmaceutical and medical device testing.

We extend our heartfelt thanks to the UP Promote Pharma Council, Government of Uttar Pradesh, and the organizing team for this prestigious opportunity, which underscored UP's ambition to become India's leading MedTech hub with its 350-acre Medical Device Park and supportive policies.

Mr. Kamal Kardani, Manager - Analytical Development, attended the InjectablesX Conference (Complex Injectables for Highly Regulated Markets) on January 29-30, 2026, at Novotel Hotel, Ahmedabad.

Organized by Glostem, the event featured expert sessions on portfolio development, API characterization (Q1/Q2/Q3 sameness, reverse engineering), rational design of long-acting injectables, nanomaterials, drug-device combinations, IVRT/IVIVC, bioequivalence (including 505(b)(2) approaches), and sterility assurance in manufacturing.

Mr. Kamal Kardani's participation strengthens Accuprec's expertise in complex parenteral products for regulated markets.

On the eve of 14th January 2026, the Accuprec team soared high with the spirit of Uttarayan during Makar Sankranti at our Ahmedabad facility!  Focusing on the thrill of kite flying, team gathered in the lawn area of Accuprec facility to fly vibrant Kites into the sky, filling the air with colorful kites and friendly competition.

The event brought everyone together for fun, laughter, and team bonding under the sunny skies— a perfect way to celebrate the harvest festival

The Accuprec team enjoyed a refreshing 2-day team outing to the beautiful city of Udaipur and sacred Nathdwara. The trip was filled with high-energy team building activities, lots of fun and enjoyment, friendly competitions, laughter, and great bonding moments in Rajasthan’s scenic beauty.

A special highlight was the peaceful and devotional darshan at Shrinathji Temple in Nathdwara, bringing serenity and blessings to the entire team. We also conducted an inspiring Vision 2026 activity, where every employee penned down their personal, professional, financial, educational, spiritual, social,  visions and goals for the year ahead.

The getaway blended adventure, spirituality, reflection, and strong team spirit—leaving everyone recharged and motivated!